New biweekly diabetes pill could replace daily dosing
NCT ID NCT07198932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare two diabetes medications, cofrogliptin and linagliptin, when added to insulin therapy in Chinese adults with type 2 diabetes. About 594 participants will take either a biweekly or daily pill alongside their usual insulin. Researchers will track blood sugar control, side effects, and other health measures over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cofrogliptin and linagliptin
What this could lead to
If successful, this could show that a biweekly pill (cofrogliptin) works as well as a daily pill (linagliptin) for controlling blood sugar in people with type 2 diabetes who already use insulin.
What could go wrong
This is a real-world observational study, not a controlled trial, so results may be less reliable. It is also limited to Chinese adults, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Hebei University
Baoding, China
-
Beijing Luhe Hospital Affiliated to Capital Medical University
Beijing, China
-
Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University
Shanghai, China
-
Shanghai Changzheng Hospital
Shanghai, China
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
-
Xi'an International Medical Center Hospital
Xi'an, China
-
the First Medical Center of Chinese PLA General Hospital
Beijing, China